ID
26475
Beskrivning
Study ID: 101468/190 Clinical Study ID: SKF-101468/190 Study Title:A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication: Restless Legs Syndrome This is the Patient Continuation Withdrawal form.
Nyckelord
Versioner (2)
- 2017-10-03 2017-10-03 -
- 2017-10-18 2017-10-18 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
18 oktober 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Patient Continuation Withdrawal GSK Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/190
Patient Continuation Withdrawal GSK Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/190
Beskrivning
INVESTIGATOR SIGNATURE
Alias
- UMLS CUI-1
- C2346576
Similar models
Patient Continuation Withdrawal GSK Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/190
C0392360 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])